BridgeBio Pharma (BBIO) EV/FCF: History & Chart

BridgeBio Pharma, Inc.(BBIO)

Biotechnology · Palo Alto, CA

$66.14-1.11 (-1.65%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.

Palo Alto, CA

999 employees

www.bridgebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Neil Kumar

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
BridgeBio Pharma, Inc. (BBIO)	$12.95B	N/A	N/A	N/A	N/A
ICON Public Limited Company (ICLR)vs ›	$12.89B	11.48x	13.58x	22.07x	29.19x
Corcept Therapeutics Incorporated (CORT)vs ›	$13.19B	122.42x	62.88x	43.79x	33.80x
Baxter International Inc. (BAX)vs ›	$12.52B	29.56x	49.28x	50.10x	47.01x
Penumbra, Inc. (PEN)vs ›	$12.49B	57.89x	68.79x	529.85x	1631.27x
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.17B	34.81x	37.68x	160.37x	160.37x
Encompass Health Corporation (EHC)vs ›	$12.00B	35.64x	32.18x	40.80x	48.31x
Ascendis Pharma A/S (ASND)vs ›	$14.16B	35.54x	246.04x	246.04x	246.04x
DaVita Inc. (DVA)vs ›	$11.47B	13.41x	17.87x	17.67x	17.78x
Bio-Techne Corporation (TECH)vs ›	$11.36B	43.26x	40.44x	44.53x	48.27x

NAME

MARKET CAP

EV/FCF RATIO

TTM

BridgeBio Pharma, Inc. (BBIO)

$12.95B

N/A

ICON Public Limited Company (ICLR)vs ›

$12.89B

11.48x

13.58x

22.07x

29.19x

Corcept Therapeutics Incorporated (CORT)vs ›

$13.19B

122.42x

62.88x

43.79x

33.80x

Baxter International Inc. (BAX)vs ›

$12.52B

29.56x

49.28x

50.10x

47.01x

Penumbra, Inc. (PEN)vs ›

$12.49B

57.89x

68.79x

529.85x

1631.27x

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.17B

34.81x

37.68x

160.37x

Encompass Health Corporation (EHC)vs ›

$12.00B

35.64x

32.18x

40.80x

48.31x

Ascendis Pharma A/S (ASND)vs ›

$14.16B

35.54x

246.04x

DaVita Inc. (DVA)vs ›

$11.47B

13.41x

17.87x

17.67x

17.78x

Bio-Techne Corporation (TECH)vs ›

$11.36B

43.26x

40.44x

44.53x

48.27x

EV/FCF Ratio: N/A

BBIO EV/FCF Ratio Metrics

BBIO Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics